GLO1

Across TCGA pan-cancer cohorts, GLO1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated GLO1 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GLO1 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GLO1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where GLO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.467	0.286	.003	24	view →
CCRCC	DFS	Median	IV	0.781	0.220	.017	21	view →
LUAD	DFS	Quartile	All	0.869	0.390	.008	9	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	DFS	Median	All	0.814	0.602	.011	4	view →
UCEC	OS	Median	All	0.913	0.983	.033	2	view →
HNSC	DFS	Quartile	III,IV	1.000	0.891	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

GLO1–PDAC (OS)

Open the PDAC breakdown →